Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.
Minerals Technologies Inc. (NYSE: MTX) shares declined 4.08 percent to close at $44.70 a share Tuesday. The stock traded between $44.67 and $46.31 on volume of 199,000 shares traded. Analysts at KeyBanc have recently initiated coverage on the company with a "hold" rating. Shares of Minerals Technologies have gained approximately 22.0 percent year-to-date.
Find out more about Minerals Technologies including full access to the free equity report at:
Peregrine Semiconductor Corp. (NASDAQ: PSMI) shares increased 1.10 percent to close at $11.02 a share Tuesday. The stock traded between $10.91 and $11.32 on volume of 145,457 shares traded. Analysts at JMP Securities have recently initiated coverage on the company with an "outperform" rating and a price target of $15.00. Shares of Peregrine Semiconductor have fallen approximately 28.0 percent year-to-date.
Find out more about Peregrine Semiconductor including full access to the free equity report at:
Select Comfort Corp. (NASDAQ: SCSS) shares increased 2.15 percent to close at $23.73 a share Tuesday. The stock traded between $23.46 and $24.26 on volume of 1.36 million shares traded. Analysts at Longbow have recently upgraded the company rating to "buy" from "neutral". Shares of Select Comfort have fallen approximately 10.0 percent year-to-date.
Find out more about Select Comfort including full access to the free equity report at:
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares declined 3.08 percent to close at $33.97 a share Tuesday. The stock traded between $33.81 and $35.49 on volume of 1.45 million shares traded. Analysts at Citigroup have recently initiated coverage on the company with a "neutral" rating. Shares of Sarepta Therapeutics have gained approximately 32.0 percent year-to-date.
Find out more about Sarepta Therapeutics including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing
Leave a comment...